AeroLeads people directory · profile

Peter Spargo Email & Phone Number

Retired Chemistry Manufacturing & Controls Professional at Spargo Pharma Consulting
Location: Kent, England, United Kingdom 10 work roles 3 schools
1 work email found @veronapharma.com LinkedIn matched
✓ Verified July 2026 4 data sources Profile completeness 100%

Contact Signals · 1 work email

Work email p****@veronapharma.com
LinkedIn Profile matched
3 free lookups remaining · No credit card
Current company
Spargo Pharma Consulting
Role
Retired Chemistry Manufacturing & Controls Professional
Location
Kent, England, United Kingdom

Who is Peter Spargo? Overview

A concise factual answer block for searchers comparing this professional profile.

Quick answer

Peter Spargo is listed as Retired Chemistry Manufacturing & Controls Professional at Spargo Pharma Consulting, based in Kent, England, United Kingdom. AeroLeads shows a work email signal at veronapharma.com and a matched LinkedIn profile for Peter Spargo.

Peter Spargo previously worked as Retired at Spargo Pharma Consulting and Independent Consultant at Spargo Pharma Consulting. Peter Spargo holds Postdoctoral Research Fellow, Synthetic Organic Chemistry from Columbia University.

Company email context

Email format at Spargo Pharma Consulting

This section adds company-level context without repeating Peter Spargo's masked contact details.

{first}.{last}@veronapharma.com
86% confidence

AeroLeads found 1 current-domain work email signal for Peter Spargo. Compare company email patterns before reaching out.

Profile bio

About Peter Spargo

A highly effective, experienced and proactive life sciences professional with an outstanding track record of achievement. As a key member (SVP CMC) of the Executive Committee at Novexel (Paris), managed the progression of a rich and challenging portfolio of anti-infective assets from preclinical through to Phase II clinical trials, and positioning for Phase III readiness, leading ultimately to the successful sale of the company to AstraZeneca in 2010 for ~$500M.Combining world class scientific knowledge and ability with inspirational leadership and man-management skills, was a significant enhancer and developer of the European Chemical Research and Development and Pharmaceutical Sciences functions within Pfizer Global R & D, leading efficient and effective multi-disciplinary project delivery and international portfolio management in both the Human and Animal Health sectors. Expanded Scientific Update's expert consultancy capabilities and capacity, and further developed their portfolio of training courses and conferences in process and medicinal chemistry. Consultancy expertise lies in the strategic management of CMC aspects of small molecule pharmaceutical development programmes, embracing drug substance (API) and drug product, including the selection and management of outsourced R & D and manufacturing contracts for virtual pharma. Also provision of independent expert-witness testimony in pharma patent litigation.Specialties: Chemistry Manufacturing and Controls (CMC)Pharmaceutical Process ChemistryAPI Manufacture and SupplyExpert Witness Testimony

Listed skills include Chemistry, Expert Witness, Pharmaceuticals, and Process Chemistry.

Current workplace

Peter Spargo's current company

Company context helps verify the profile and gives searchers a useful next step.

Spargo Pharma Consulting
Spargo Pharma Consulting
Retired Chemistry Manufacturing & Controls Professional
10 roles · 39 years

Peter Spargo work experience

A career timeline built from the work history available for this profile.

Retired

Current
Spargo Pharma Consulting
Sep 2024 - Present

Independent Consultant

Current
Spargo Pharma Consulting

Provision of independent advice relating to the strategic management of CMC aspects of small molecule pharmaceutical development programmes, embracing drug substance (API) and drug product, including the selection and management of outsourced R & D and manufacturing contracts for virtual pharma. Also provision of independent expert-witness testimony in pharma patent litigation.

Oct 2010 - Present

Svp Cmc

Verona Pharma
2014 - Nov 2024

Senior Vice President

Creabilis Sa

- Key responsibility: The development, third party manufacture and supply of Novexel’s Investigational Medicinal Products, embracingo Chemical process research and developmento Active Pharmaceutical Ingredient (API) manufacture and cost reductiono Formulation identification and developmento Drug product manufacture and clinical supply logisticso Analytical, regulatory and quality aspects associated with the aboveo Development and implementation of short and long term manufacturing and supply chain strategies

2011 - 2013 ~2 yrs

Senior Vice President Cmc / Vice President Cmc

Fr

- Member of the Executive Team responsible for managing the progression of a portfolio of anti-infective assets (including NXL103 and NXL104) from preclinical through to Phase II clinical trials (and positioning for Phase III readiness), leading ultimately to the successful sale of the company to AstraZeneca for ~$500M- Key responsibility: The development, third party manufacture and supply of Novexel’s Investigational Medicinal Products, embracingo Chemical process research and developmento Active Pharmaceutical Ingredient (API) manufacture and cost reductiono Formulation identification and developmento Drug product manufacture and clinical supply logisticso Analytical, regulatory and quality aspects associated with the aboveo Development and implementation of short and long term manufacturing and supply chain strategies

Dec 2007 - Oct 2010

Managing Director / Scientific Director

Crowborough, East Sussex, Gb

- Consultancy and CMC management for a range of pharmaceutical and biotech companies, as well as Universities, providing detailed technical advice and strategic guidance, with customers across Europe, USA, Canada, Australia, Singapore- Pharmaceutical Operations Development Advisory Board Member, Vertex Pharmaceuticals- CMC due diligence exercises on novel pharmaceutical chemical entities prior to licensing deals and investments- Expert witness testimony in UK Royal Courts of Justice regarding patent validity challenges relating to perindopril, and in other territories regarding patent validity challenges for the world’s largest selling pharmaceutical product, Lipitor (atorvastatin). - Led technical scoping project for new UK Bioprocessing Centre at Centre for Process Innovation (CPI)- Performed technical and market surveys for University spinout companies (e.g. PhosphonicS)- Managed CMC aspects of development projects for biotech companies, through third party contractors- Taught Chemical Development and Scale-Up course to professional industrial chemists- Researched, developed and personally delivered two completely new training courses (on Green Chemistry and Organic Synthesis) for professional chemists

Aug 2003 - Nov 2007

Group Director, Chemical R & D

New York, New York, Us

- Directed 170 Chemical R & D staff at 3 European sites (Sandwich & Sittingbourne UK, Freiburg Germany), with two Pilot Plants, a kilolab and a number of chemistry laboratories. - Ensured efficient and effective delivery of the Pfizer European Human Health and Animal Health project portfolios, some 25 projects spanning the complete spectrum from Discovery through Exploratory Development, Full Development and Product Enhancement. Responsible for the design, development and delivery of commercially viable synthetic routes to drug development candidates, supplying drug substance to meet the demands of toxicology, clinical and formulation development programmes, and generating knowledge to underpin regulatory filings and transfer to commercial manufacturing.- Led Pfizer’s Worldwide Pharmaceutical Sciences Veterinary Medicine Portfolio, with a budget of ~$23M and multi-disciplinary (drug product and drug substance) projects sited in Groton (CT, USA), Kalamazoo (MI, USA) and Sandwich (UK). Also accountable for post-Pharmacia integration Animal Health business continuity in Worldwide Pharm Sci.- By personal initiative, led and championed major development cost reduction initiative (ultimately coined “The Spargo-5”) for Veterinary Medicine, resulting in projected halving of Pharm Sci development costs relative to comparable Human Health projects- Took over leadership of two fragmented multi-disciplinary early candidate management teams (ECMTs) (consisting of clinicians, biologists, chemists, pharmacists, toxicologists, regulatory experts and project management), winning senior management support for unprecedented scientific proposals in a ground-breaking therapeutic area. - Member of Worldwide Pharmaceutical Sciences Leadership Team and Chemical R & D Line Council. Proposed, set up and chaired “Succeeding Through People” subgroup, delivering simple but effective mechanisms for leveraging the scientific expertise across global Chemical R & D.

2001 - Aug 2003

Director / Manager, Chemical R & D

New York, New York, Us

- Appointed Section Head, then Manager, then Director of increasing numbers of Chemical R & D laboratory staff at Sandwich.- Completed successful regulatory submissions for new drugs in EU, USA and Japan, including key leadership roles for eletriptan and selamectin.- As a leading member of the CRD Management Team, made major contributions towards a doubling of headcount to 120 in a 3 year period, and the introduction of new specialist functions including laboratory automation and operations support. Facilitated pre- and post-merger staff motivation and deployment. - Through personal initiative, created and chaired the Sandwich CRD team of senior chemists resulting in improved quality, flexibility and operational efficiency.- Chaired Sandwich Pharmaceutical Sciences Veterinary Medicine Portfolio Management Group (VMPMG) leading the delivery of UK based Vet Med projects.

1996 - 2001 ~5 yrs

Chemical Process Research & Development Chemist

New York, New York, Us

- Identified, developed and scaled up manufacturing processes for new drug candidates, including one for which as Pharmaceutical Sciences Project Coordinator, led drug substance and drug product activities from Discovery through to successful commercialisation in record time (5 years).- Responsible for technical liaison with R&D staff at other sites in the UK and USA.

1990 - 1996 ~6 yrs

Medicinal Chemist

New York, New York, Us

- Led a small laboratory team designing and synthesising new compounds for biological and pharmacological testing.

1988 - 1990 ~2 yrs
3 education records

Peter Spargo education

Postdoctoral Research Fellow, Synthetic Organic Chemistry

Columbia University

Phd, Synthetic Organic Chemistry

University Of Cambridge

Bachelor'S Degree, Natural Sciences (Chemistry)

University Of Cambridge
FAQ

Frequently asked questions about Peter Spargo

Quick answers generated from the profile data available on this page.

What company does Peter Spargo work for?

Peter Spargo works for Spargo Pharma Consulting.

What is Peter Spargo's role at Spargo Pharma Consulting?

Peter Spargo is listed as Retired Chemistry Manufacturing & Controls Professional at Spargo Pharma Consulting.

What is Peter Spargo's email address?

AeroLeads has found 1 work email signal at @veronapharma.com for Peter Spargo at Spargo Pharma Consulting.

Where is Peter Spargo based?

Peter Spargo is based in Kent, England, United Kingdom while working with Spargo Pharma Consulting.

What companies has Peter Spargo worked for?

Peter Spargo has worked for Spargo Pharma Consulting, Verona Pharma, Creabilis Sa, Novexel, and Scientific Update Llp.

How can I contact Peter Spargo?

You can use AeroLeads to view verified contact signals for Peter Spargo at Spargo Pharma Consulting, including work email, phone, and LinkedIn data when available.

What schools did Peter Spargo attend?

Peter Spargo holds Postdoctoral Research Fellow, Synthetic Organic Chemistry from Columbia University.

What skills is Peter Spargo known for?

Peter Spargo is listed with skills including Chemistry, Expert Witness, Pharmaceuticals, and Process Chemistry.

Find 750M verified contacts

Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.